featured
Association of Minimal Residual Disease Status 1 Year After Autologous HCT and Lenalidomide Maintenance With Long-Term Overall Survival in Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival
J. Clin. Oncol 2024 May 03;[EPub Ahead of Print], MC Pasquini, PK Wallace, B Logan, M Kaur, JD Tario, A Howard, Y Zhang, C Brunstein, Y Efebera, N Geller, S Giralt, P Hari, MM Horowitz, J Koreth, A Krishnan, H Landau, G Somlo, N Shah, E Stadtmauer, DT Vogl, DH Vesole, PL McCarthy, T HahnFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.